Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.01 138 01:00:00
Bid Price Offer Price High Price Low Price Open Price
1.01 1.02 1.01 1.01 1.01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 142.34 113.82 8.28 12.2 1,388
Last Trade Time Trade Type Trade Size Trade Price Currency
08:00:25 UT 138 1.01 USD

Biopharma Credit (BPCR) Latest News

More Biopharma Credit News
Biopharma Credit Takeover Rumours

Biopharma Credit (BPCR) Discussions and Chat

Biopharma Credit Forums and Chat

Date Time Title Posts
16/9/202014:22::: BIOPHARMA CREDIT PLC :::32

Add a New Thread

Biopharma Credit (BPCR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-09-21 16:17:251.012323.23O
2020-09-21 16:08:511.017879.17O
2020-09-21 15:35:061.01981990.81UT
View all Biopharma Credit trades in real-time

Biopharma Credit (BPCR) Top Chat Posts

Biopharma Credit Daily Update: Biopharma Credit Plc is listed in the Unknown sector of the London Stock Exchange with ticker BPCR. The last closing price for Biopharma Credit was US$1.01.
Biopharma Credit Plc has a 4 week average price of US$1.01 and a 12 week average price of US$0.97.
The 1 year high share price is US$1.03 while the 1 year low share price is currently US$0.85.
There are currently 1,373,872,373 shares in issue and the average daily traded volume is 1,044,332 shares. The market capitalisation of Biopharma Credit Plc is £1,387,611,096.73.
speedsgh: Half-year Report - HTTPS:// Pedro Gonzalez de Cosio, CEO and co-founder of Pharmakon Advisors L. P., the Investment Manager of BioPharma Credit PLC, said: "During the first six months of 2020, Covid-19 has brought exceptional challenges to the global economy resulting in volatile conditions for many sectors and a significant reduction in global dividends. However, as a result of the Company's uncorrelated revenue stream, dividend payments have continued uninterrupted towards the ongoing annual target of 7 cents per share, just above a 7% dividend yield to our investors on the 30 June share price. It is the Company's objective to continue to offer a highly attractive long-term source of income uncorrelated to other markets. "The Company's investment activity in deploying specialised debt investments such as senior secured loans backed by important life science products has continued as normal with one significant new investment in Collegium Pharmaceuticals during the period and additional follow-on commitments in addition to some attractive pre-payments post-period end. "The environment continues to be attractive for the Company's investment strategy given the considerable and growing capital needs of the sector. This will be potentially enhanced by an anticipated increase in sector M&A activity and a slowdown in equity issuance that has tended historically to lead to a greater appetite for fixed income as a source of capital for the life sciences industry."
rambutan2: More good news. The hefty Invesco overhang is gone: I found this relevantly interesting: hTtps://
jonwig: WilliamC - NAV at 102c is higher than the share price. They won't try new equity until they can reverse that. I think ram was suggesting debt.
Biopharma Credit share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200922 07:31:05